Date | Title | Description |
04.11.2024 | Last week recap: More than 60 tech funding deals worth over €1B | Last week, we tracked more than 60 tech funding deals worth over €1 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe.
The top three industries that raised the most were marketing (€471 million... |
20.10.2024 | Gladia: AI Transcription And Audio Intelligence Company Raises $16 Million (Series A) | Gladia, an AI-based transcription and audio intelligence provider, announced it has completed a $16 million Series A funding round. The company will use the funding to develop an end-to-end audio infrastructure, starting with a new real-tim... |
18.03.2024 | Anthropic-backer Menlo Ventures is preparing for a 'gold rush' of AI infrastructure startups. Here's why. | Startups Anthropic-backer Menlo Ventures is preparing for a 'gold rush' of AI infrastructure startups. Here's why.
Samantha Stokes and Darius Rafieyan
2024-03-18T09:00:01Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The l... |
10.10.2023 | Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn ... | - |
11.04.2023 | Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more | Mark Adams. (Adaptive Photo)
— Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing.
Adams joined the Seattle-based biotech giant more than three years ago. The fi... |
10.04.2023 | Tech Moves: Halo leader departing; Remitly adds board directors; drone vet lands at Rantizo | Phyllis Campbell (left) and Ryno Blignaut.
— Seattle-based fintech company Remitly added two new board members: Ryno Blignaut and Phyllis Campbell.
Blignaut is an investor with Silicon Valley venture firm Khosla Ventures and previously serv... |
11.01.2022 | Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct | SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medici... |
11.01.2022 | Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct | SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Bi... |
19.10.2021 | Sage, Biogen head to FDA with $3.1B depression drug; Sana puts down $50M to tap Beam's CRISPR tech | Weeks after announcing they would drop a pair of studies deemed unnecessary to file the depression drug zuranolone for approval, Sage and Biogen are going for it.
Following a pre-NDA meeting with the FDA, the partners say ... |
15.07.2021 | Catalent lands 2 new partnerships, including for glioblastoma drug; US drops $153M into pandemic preparedness | Back just before the pandemic hit the world in early 2020, Moderna’s shares were trading right around $20 a share. Today, it’s above $250 a share — up 3% this morning — and the market cap has pierced the $100 billion mark.
Working solo, the... |
15.07.2021 | Catalent lands 2 new partnerships, including for glioblastoma drug; US drops $153M into pandemic preparedness | It’s been a quiet few weeks for one of the busiest CDMOs out there, but Catalent broke its lull with the announcement of two partnerships this week.
Curtana Pharmaceuticals, an Austin, TX-based preclinical company, announc... |
15.07.2021 | Eli Lilly partners with Alzheimer's center for PhIII study; New tuberculosis consortium emerges in $218M+ project | As Eli Lilly preps to submit its Alzheimer’s candidate donanemab to the FDA following Biogen’s Aduhelm approval, the Big Pharma is working to collaborate with a Phoenix research institute to advance the program’s Phase II... |
15.07.2021 | A Chinese I/O biotech looking to turn around an old Novartis program gets a new fundraise after launching PhIII study | Close to a year after pulling in its last private fundraise, Chinese immuno-oncology biotech Adlai Nortye is back with another nine-figure round. And it comes as it seeks to continue pushing forward a former experimental... |
15.07.2021 | Catalent lands 2 new partnerships, including for glioblastoma drug; US drops $153M into pandemic preparedness | Shankar Ramaswamy learned a lot when he went to work for his older brother Vivek at Axovant. He also gained some important relationships. And they are both coming into play as he takes his newly-founded gene therapy company up to the next l... |
15.07.2021 | EXCLUSIVE: Shape Therapeutics raises $112M in bid to make RNA editing — and a whole lot else — a reality | Two years after spinning out of CRISPR pioneer Prashant Mali’s lab, Shape Therapeutics has a lot more cash and a slightly new mission.
The company originally launched in 2019 with plans to develop therapies around a new fo... |
15.07.2021 | Discovery by Shanghai scientists inspires new plan of ATTEC for protein degradation | In a review penned weeks ago, Craig Crews — the Yale scientist credited with the discovery of PROTACs — reflected on how, in the two decades since he helped launch the field, targeted protein degradation has moved beyond the... |
15.07.2021 | Catalent lands 2 new partnerships, including for glioblastoma drug; US drops $153M into pandemic preparedness | A unicorn multiple times over, Sana Biotechnology hit Nasdaq running in February with its next-gen cell therapies still months away from the clinic. Now, Sana is looking to the future once again and clearing out some elbow room for its manu... |
15.07.2021 | Catalent lands 2 new partnerships, including for glioblastoma drug; US drops $153M into pandemic preparedness | The analysts still left trying to determine if Gilead’s once-big collaborator Galapagos has anything of value to offer in the pipeline were left either shaking their heads Wednesday evening or looking for some hard-to-find silver linings in... |
15.07.2021 | Making a name for itself in Covid-19 testing, Hong Kong's Prenetics is the latest biotech SPAC merger — report | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
A Hong Kong biotech researching genetic sequencing and developing rapid Covid-19 tests is reportedly se... |
15.07.2021 | Already sitting on a major stem cell bank, Generate looks to grow its regenerative medicines business | Generate Life Sciences is the largest private newborn stem cell biorepository, and with the announcement of its own in-house manufacturing facility, the company is looking to grow its regenerative medicine pipeline... |
14.07.2021 | FDA chides Amgen over misleading banner ad for Neulasta | In its second untitled letter of 2021, the FDA’s Office of Prescription Drug Promotion raised questions about Amgen’s misleading banner ads for its blockbuster bone marrow stimulant Neulasta.
OPDP notes that certain cla... |
14.07.2021 | Sana Biotechnology : Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates | Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies
Facility Able to Support Clinical Trial and Early Commercial Launches of Multiple Programs
State-of-the-Art Manufacturing Facility to be Located in San Fran... |
14.07.2021 | Tom Lynch moves to restructure Fred Hutch as academia, industry continue to push cell therapy into solid tumors | By the time former Bristol Myers Squibb CSO Tom Lynch stepped in to run the Fred Hutch Cancer Research Center last year, both the potential and limits of the institute’s preclinical research had become clear.
The institute... |
02.03.2021 | How SPACs are changing the IPO game: Equity ownership of founders a big consideration | SPACs are hot right now, and one of the reasons is they can keep more equity in the hands of founders. (GeekWire Illustration / Canva Image, adrian825)
A few weeks ago, a longtime GeekWire reader sent a note expressing shock that Sana Biote... |
05.02.2021 | Sana Biotechnology hit a $6.5 billion valuation after its IPO. Here are the execs and investors who made the most from the record offering. | Steve Harr Juno Therapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Sana Biotechnology went public before testing any treatments in people.
The cell and gene therapy s... |
04.02.2021 | Sana Snags $587.5M IPO to Catapult Cell Therapies into the Clinic | - |
04.02.2021 | Sana joins Nasdaq with blockbuster $587M IPO | Sana’s gene editing tech could provide treatments for a number of diseases. (Image: IPO filing)
Sana Biotechnology raised $587.5 million in an initial public offering, a significant cash haul that the 3-year-old Seattle company will use to ... |
03.02.2021 | Sana Biotechnology boosts IPO range, looks to raise $517 million | Sana’s technology (screen grab via IPO filing)
Editor’s note: Sana Biotechnology priced shares on Wednesday evening, raising $587.5 million. See full story here.
Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of ... |
03.02.2021 | Sana Biotechnology boosts IPO range, looks to raise $517 million | Sana’s technology (screen grab via IPO filing)
Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street.
Sana boosted the number of ... |
13.01.2021 | Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO | - |
16.12.2020 | Seattle area boasts 10 fast-growing unicorns: Can you name the billion-dollar startups? | There are 10 unicorn startups in the Seattle area valued at $1 billion or more. (Shutterstock Photo)
The unicorn — that supposed elusive creature of the startup world — is becoming a bit more commonplace in these parts.
There are now 10 uni... |
23.10.2020 | Sana CEO reveals details about stealthy gene therapy startup that has raised more than $700M | Luke Timmerman interviews Sana Biotechnology CEO Steve Harr at the GeekWire Summit this week.
Sana Biotechnology CEO Steve Harr shed more light on one of most secretive, heavily funded startups in Seattle and the global biotech industry — d... |
09.09.2020 | Synthetic Biology Startups Raised $3 Billion In The First Half Of 2020 | (Getty Images/Luis Alvarez) |
23.06.2020 | Sana Biotechnology raises more than $700M for cell, gene therapy efforts | The company is developing cell as well as gene therapies and plans to use the money it has raised on its discovery and development efforts. It announced its launch in January of last year, with the stated goal of developing means of in vivo... |
02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments.
“ARCH is st... |
03.05.2019 | Revealed: GeekWire Awards 2019 winners crowned as we celebrate the best of Pacific Northwest tech | (GeekWire Photo / Taylor Soper)
The strength and success of the people and companies across the Pacific Northwest tech ecosystem was on full display Thursday night at the GeekWire Awards.
It was so much fun celebrating with more than 900 of... |
08.04.2019 | Startup of the Year nominees share tips for success — cast your vote now for the GeekWire Awards | Seattle startup Crowd Cow accepts the Startup of the Year award at the 2018 GeekWire Awards. (GeekWire Photo / Kevin Lisota)
A quick gander at the GeekWire 200, our index of Pacific Northwest startups, shows the density of up-and-coming tec... |
20.03.2019 | Flagship Pioneering raises $824M in new fund | “With each year of company origination, as we honed our pioneering approach, we have steadily increased our capacity to launch transformative ventures,” said Flagship CEO Noubar Afeyan, in a statement. “Our new fund will complement our orig... |
07.01.2019 | Former Juno execs unveil Sana, a new cell engineering biotech that’s reportedly raising more than $800M | Hans Bishop at the 2016 GeekWire Summit. (GeekWire Photo / Dan DeLong)
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing.
Backed... |
- | Sana Biotechnology raises more than $700M for cell, gene therapy efforts | A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.
Seattle-based Sana Bio... |
- | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | Two large venture capital firms have raised nearly $2.6 billion that they plan to invest in life sciences startups, they said in announcements Thursday.
Cambridge, Massachusetts-based Flagship Pioneering said it had closed a $1.1 billion ca... |
- | Flagship Pioneering raises $824M in new fund | A life sciences-focused venture capital firm has raised more than $800 million for its latest fund.
Cambridge, Massachusetts-based Flagship Pioneering said Wednesday that it had raised $824 million for the capital pool, Special Opportunitie... |